Status: Not yet recruiting
211At-MABG in Adults With Advanced Neuroendocrine Cancers
Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standard 3+3 design with an expansion cohort at the recommended phase two dose (RP2D).
Participants needed: 16
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: University of PennsylvaniaUpdated: Jun 22, 2026Locations: 1
Eligibility criteria
Adult patients, at least 18 years of age [+11]
Women who are pregnant or breast-feeding will not be eligible for this study. [+5]